Suven Pharma reported a 56.6% drop in net profit for the December quarter compared to the same period last year. Revenue also decreased by 37.9%. The decline was attributed to lower EBITDA and global supply chain destocking. However, their pharma CDMO business showed growth of 24% in the first 9 months of FY24. The CEO remains confident in achieving medium-term growth through ongoing discussions.